In this episode, Medicom’s correspondent covers 6 presentations from the Nordic Lung Congress (NLC 2022), held in Copenhagen, Denmark, from 01-03 June 2022.
The topics discussed are:
- Vaping amongst adolescents: a worrying trend
According to Finnish research, there is a strong need to strengthen preventive policies on e-cigarettes to prevent adolescents to fall prey to the tobacco epidemic. This includes comprehensive and strict e-cigarette regulations, that extend to all tobacco regulations. Also, targeted regulation/enforcement that considers the innovative characteristics of these products is required. - Link between asthma and decreased fertility is being unravelled in the PRO-ART study
The association between asthma and decreased fertility is currently being investigated in the PRO-ART study. The results will hopefully shed some new light on the underlying mechanism and enhance our knowledge of this complicated interplay. - EILO is often misdiagnosed
Exercise-induced laryngeal obstruction (EILO) is often mistaken for asthma. In fact, it is a very different condition that needs a specific management strategy mainly focused on making the patient understand what EILO is. Speech training may also prove beneficial, but an inhaler should not be part of therapy. - No oral corticosteroids before a confirmed diagnosis of ILD
Data from a Finnish study assessing the pre-operative risk factors for transbronchial lung cryobiopsy (TBLC) complications in patients with interstitial lung disease (ILD) showed that it might not be wise to use oral corticosteroids in these patients before a confirmed diagnosis. Also, a severe cough should be investigated before TBLC is considered. - Physical activity for asthma patients improves asthma control
Although it can be challenging to prescribe exercise to asthma patients, physical activity proves to be a valuable intervention as it improves asthma control. However, patients should not overdo it, as excessive vigorous training increases the risk of developing asthma and asthma-related conditions. - Social distancing led to reduced number of exacerbations in bronchiectasis patients
Social distancing during the COVID-19 pandemic reduced the exacerbation risk in bronchiectasis patients. The daily symptoms that these patients experience, such as phlegm and cough, were not significantly reduced. Besides, patients did not experience a heightened sense of anxiousness as a result of social distancing.
Enjoy listening!
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
Editors »
« Letter from the Editor Next Article
Editors »
Table of Contents: NLC 2022
Featured articles
Respiratory Disease and Physical Activity
Physical activity improves asthma control
Exercise training for IPF patients is feasible but access needs to be improved
Respiratory Disease and Reproduction
PRO-ART study: unravelling the link between asthma and subfertility
Early-onset and uncontrolled asthma: strong association with recurrent pregnancy loss
Palliative Care in Respiratory Diseases
Advance care planning
Biologics in Asthma
Treatable Traits in Obstructive Airway Diseases
Targeting treatable traits allows a personalised approach to management of (severe) asthma
Bronchiectasis
Challenges in Upper Airway Diseases
Exercise-induced laryngeal obstruction (EILO) is often misdiagnosed
The ULANC Group: working together in CRSwNP/asthma
Interstitial Lung Diseases (ILD)
Rheumatoid arthritis-associated ILD
Thoracic ultrasound: a new diagnostic imaging tool in RA-ILD?
Update on treatment of fibrotic ILD
Respiratory Failure
Lung Cancer Screening in the Nordics
Points of interest for radiologists screening for lung cancer
E-cigarettes
E-cigarettes impose detrimental effects on health
Effects of passive vaping in COPD patients
Vaping amongst adolescents: an alarming trend
Tuberculosis and Sarcoidosis
Detection of latent TB infection key to preventing the spread of the disease
Related Articles
August 17, 2022
Fatigue syndrome in sarcoidosis
August 17, 2022
New antigens in sarcoidosis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com